Health CareHealth Care Equipment & Services
  • Price (AUD)135.10
  • Today's Change-2.70 / -1.96%
  • Shares traded143.55k
  • 1 Year change60.47%
  • Beta0.6284
Data delayed at least 20 minutes, as of Oct 21 2016 06:10 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Cochlear Ltd grew revenues 22.14% from 925.63m to 1.13bn while net income improved 29.54% from 145.84m to 188.92m.
Gross margin71.93%
Net profit margin16.71%
Operating margin23.23%
Return on assets20.62%
Return on equity47.00%
Return on investment32.06%
More ▼

Cash flow in AUDView more

In 2016, Cochlear Ltd did not generate a significant amount of cash. However, the company earned 185.11m from its operations for a Cash Flow Margin of 16.37%. In addition the company used 50.13m on investing activities and also paid 130.89m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share7.84
Tangible book value per share3.92
More ▼

Balance sheet in AUDView more

Cochlear Ltd has a Debt to Total Capital ratio of 30.11%, a higher figure than the previous year's 12.54%.
Current ratio2.16
Quick ratio1.55
Total debt/total equity0.4308
Total debt/total capital0.3011
More ▼

Growth rates in AUD

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 21.05% and 29.51%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Medical Equipment & Supplies industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)3.24%
Div growth rate (5 year)0.44%
Payout ratio (TTM)69.64%
EPS growth(5 years)0.8695
EPS (TTM) vs
TTM 1 year ago
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.